These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14621970)

  • 41. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers.
    Liao YH; Brown MB; Jones SA; Nazir T; Martin GP
    Int J Pharm; 2005 Nov; 304(1-2):29-39. PubMed ID: 16181753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers.
    Gupta A; Stein SW; Myrdal PB
    J Aerosol Med; 2003; 16(2):167-74. PubMed ID: 12823910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers.
    Tam JM; Engstrom JD; Ferrer D; Williams RO; Johnston KP
    J Pharm Sci; 2010 Jul; 99(7):3150-65. PubMed ID: 20187139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient.
    Lewis DA; Young PM; Buttini F; Church T; Colombo P; Forbes B; Haghi M; Johnson R; O'Shea H; Salama R; Traini D
    Eur J Pharm Biopharm; 2014 Jan; 86(1):31-7. PubMed ID: 23523547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measurement and correlation of solute solubility in HFA-134a/ethanol systems.
    Hoye JA; Myrdal PB
    Int J Pharm; 2008 Oct; 362(1-2):184-8. PubMed ID: 18647644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigating the evaporation of metered-dose inhaler formulations in humid air: single droplet experiments.
    Martin AR; Kwok DY; Finlay WH
    J Aerosol Med; 2005; 18(2):218-24. PubMed ID: 15966776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers.
    Myrdal PB; Karlage KL; Stein SW; Brown BA; Haynes A
    J Pharm Sci; 2004 Apr; 93(4):1054-61. PubMed ID: 14999741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Formulation and evaluation of novel reverse microemulsions containing salmon calcitonin in hydrofluoroalkane propellants.
    Shan Z; Tan Y; Qin L; Li G; Pan X; Wang Z; Yu X; Wang Q; Wu C
    Int J Pharm; 2014 May; 466(1-2):390-9. PubMed ID: 24657140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Consequences of not-shaking and shake-fire delays on the emitted dose of some commercial solution and suspension pressurized metered dose inhalers.
    Chierici V; Cavalieri L; Piraino A; Paleari D; Quarta E; Sonvico F; Melani AS; Buttini F
    Expert Opin Drug Deliv; 2020 Jul; 17(7):1025-1039. PubMed ID: 32551990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol.
    Peyron ID; Britto IL; Benissan LB; Tardieu BZ
    Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sub-micrometer particle production by pressurized metered dose inhalers.
    Crampton M; Kinnersley R; Ayres J
    J Aerosol Med; 2004; 17(1):33-42. PubMed ID: 15120011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of metered dose inhaler (MDI) formulations of ciclosporin.
    Marijani R; Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2007 Jan; 59(1):15-21. PubMed ID: 17227616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes.
    Wu L; Al-Haydari M; da Rocha SR
    Eur J Pharm Sci; 2008 Feb; 33(2):146-58. PubMed ID: 18083015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos.
    Sawatdee S; Hiranphan P; Laphanayos K; Srichana T
    Eur J Pharm Biopharm; 2014 Jan; 86(1):90-7. PubMed ID: 24036276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs.
    Stein SW; Sheth P; Younis US; Mogalian E; Myrdal PB
    Mol Pharm; 2015 Sep; 12(9):3455-67. PubMed ID: 26258647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy.
    Hoe S; Young PM; Rogueda P; Traini D
    AAPS PharmSciTech; 2008; 9(2):605-11. PubMed ID: 18459053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of expansion chamber geometry on atomization and spray dispersion characters of a flashing mixture containing inerts. Part II: High speed imaging measurements.
    Ju D; Shrimpton J; Bowdrey M; Hearn A
    Int J Pharm; 2012 Aug; 432(1-2):32-41. PubMed ID: 22579579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aiming for a moving target: challenges with impactor measurements of MDI aerosols.
    Stein SW
    Int J Pharm; 2008 May; 355(1-2):53-61. PubMed ID: 18191510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.